Health Economics Policy and Law最新文献_第7页

Exploring the uptake of economic evaluation in Spanish reports positioning medicines for public reimbursement. 探索经济评价在西班牙的报告定位药品为公共报销。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-01 DOI: 10.1017/S1744133124000264

Laura Vallejo-Torres, Juan Oliva-Moreno, Félix Lobo

{"title":"Exploring the uptake of economic evaluation in Spanish reports positioning medicines for public reimbursement.","authors":"Laura Vallejo-Torres, Juan Oliva-Moreno, Félix Lobo","doi":"10.1017/S1744133124000264","DOIUrl":"10.1017/S1744133124000264","url":null,"abstract":"Therapeutic positioning reports (IPTs, Spanish acronym) are a crucial tool for informing funding and pricing decisions for drugs in the Spanish healthcare system. In 2020, for the first time the inclusion of economic evaluations (EEs) was explicitly set as a primary objective in a new Action Plan aimed at consolidating IPTs. This paper seeks to examine the uptake of EE into IPTs and to compare the methods and techniques employed in the EEs conducted during the two-year pilot phase following the reform, i.e., from June 2021 to July 2023. During this period, a total of 181 IPTs were published, with 19 (10.5%) incorporating an EE section. However, out of these 19 identified IPTs, six did not actually conduct a de novo EE, and four only performed a drug cost minimisation analysis. Six IPTs conducted EE analyses following international methodological standards. Based on this review, we observe that the percentage of IPTs incorporating EEs had remained low and exhibited significant heterogeneity. The experience of these two years must be translated into lessons that can serve to reinforce the evaluation of the efficiency of medicines in Spain in the coming years.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"233-245"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How should medicines reimbursement work? The views of Spanish experts. 药品报销应如何进行？西班牙专家的观点。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-01 DOI: 10.1017/S174413312400029X

Juan Carlos Rejon-Parrilla, David Epstein, Daniel Pérez-Troncoso, Jaime Espin

引用次数: 0

Advancing healthcare decision-making for the common good: a tribute to Professor Rovira Forns. 为共同利益推进医疗保健决策：向罗维拉·福恩斯教授致敬。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-01 Epub Date: 2025-09-11 DOI: 10.1017/S1744133125100194

Joan Costa-Font, Rosa Rodriguez-Monguio

引用次数: 0

Has regional decentralisation saved lives during the COVID-19 pandemic? 在COVID-19大流行期间，区域分散是否挽救了生命？

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-01 Epub Date: 2025-05-15 DOI: 10.1017/S1744133125000052

Beatriz González López-Valcárcel, Guillem Lopez-Casasnovas

引用次数: 0

The still incomplete pursuit of universal access to medicines. 普遍获得药物的努力仍未完成。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-01 Epub Date: 2025-05-22 DOI: 10.1017/S1744133125000040

Paloma Fernández, Alicia Del Llano, Jaume Vidal, Jaime Espín, Juan E Del Llano

{"title":"The still incomplete pursuit of universal access to medicines.","authors":"Paloma Fernández, Alicia Del Llano, Jaume Vidal, Jaime Espín, Juan E Del Llano","doi":"10.1017/S1744133125000040","DOIUrl":"10.1017/S1744133125000040","url":null,"abstract":"A substantial share of the global population continues to face barriers to accessing essential medicines. While the pharmaceutical industry's business model has successfully facilitated the development of innovative medications, efforts to promote universal access to medicines (UAM) remain ineffective. This paper critically assesses the existing barriers to global access to medicines, including the role of unsuitable governance, the protection of intellectual property rights, and other market barriers such as shortages, quality shortcomings, and high prices. Furthermore, we explore a number of promising potential strategies that can help towards achieving the UAM. Specifically, we evaluate the evidence from various initiatives, including alternative models of innovation, manufacturing, procurement, intellectual property management, and structural/organisational operations. We argue that the effective realisation of UAM requires a robust framework to implement these initiatives. This framework must strike a delicate balance between addressing public health needs, incentivising research and development, and ensuring affordability. Achieving such a balance encompasses a careful oversight and collaboration between national and international regulatory bodies.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"284-296"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Health system sustainability and resilience: a preliminary provision of measurement through a "mash-up" index. 卫生系统的可持续性和复原力：通过“混搭”指数初步提供衡量标准。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-01 Epub Date: 2025-08-13 DOI: 10.1017/S1744133125100182

A McGuire, G Wharton, S Hodgson, D Kourouklis, M Jofre-Bonet, D L Tran

{"title":"Health system sustainability and resilience: a preliminary provision of measurement through a \"mash-up\" index.","authors":"A McGuire, G Wharton, S Hodgson, D Kourouklis, M Jofre-Bonet, D L Tran","doi":"10.1017/S1744133125100182","DOIUrl":"10.1017/S1744133125100182","url":null,"abstract":"We present a methodology for a new composite, quantitative \"mash-up\" index of health system sustainability and resilience, drawing on a qualitative framework developed to assess these dimensions of the health system. The paper summarises quantifiable measures of sustainability and resilience, with sustainability defined through 7 domains and 50 indicator variables, while health system resilience is based on 6 domains and 23 variables. Each domain is captured by a separate index. A composite index is constructed through aggregation across the two dimensions, and their associated domains and indicators. All indices are aggregated through estimation of a geometric means, and are bound between 0 and 100. We pilot across 5 countries over 23 years, with the ultimate aim of identifying health policy strategies for improving national health system capacities and performances; as well as facilitating policy responses to address problematic issues of sustainability and resilience. Face validity suggests that the index captures the non-resilience to the COVID-19 pandemic. The pilot study reveals considerable differences at both the dimension and domain levels within and between the examined countries, while suggesting scope for improvement in both dimensions across all countries. The index thus provides an indicative approach for temporal and spatial yardstick comparison.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"313-325"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144838181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Why drugs fail health technology assessment: a comparative analysis of health technology assessment rejections across seven OECD countries. 为什么药物不能通过卫生技术评估：七个经合组织国家卫生技术评估拒绝的比较分析。

IF 3.3 3区医学

Health Economics Policy and Law Pub Date : 2025-07-01 Epub Date: 2025-09-09 DOI: 10.1017/S1744133125100212

Filippos Papadopoulos, Erica Visintin, Ilias Kyriopoulos, Panos Kanavos

{"title":"Why drugs fail health technology assessment: a comparative analysis of health technology assessment rejections across seven OECD countries.","authors":"Filippos Papadopoulos, Erica Visintin, Ilias Kyriopoulos, Panos Kanavos","doi":"10.1017/S1744133125100212","DOIUrl":"10.1017/S1744133125100212","url":null,"abstract":"While a substantial amount of evidence exists on factors associated with positive health technology assessment (HTA) outcomes, the evidence on the same regarding rejections is scarce. Using a proprietary dataset of HTA outcomes in seven Organisation for Economic Co-operation and Development (OECD) countries, we empirically examine the factors associated with HTA rejections and study the magnitude of inter-agency differences in technology appraisals. Data were extracted from HTA reports between 2009 and 2020. The primary outcome was the probability of rejection, which was examined with respect to several regulatory, disease-related, evidence (clinical and economic) and unaddressed uncertainty variables. Multivariate logistic regression analysis was used. Out of N = 1,405 HTA assessments, the rejection rate was 12.9% (n = 181). Significant predictors of HTA rejection were submissions for drugs with cancer or orphan indications (but not both), low quality of evidence and the presence of uncertainties surrounding clinical benefit, cost-effectiveness, and economic model utility inputs. Systematic differences between agencies in their propensity for rejecting the same drugs were revealed, particularly in relation to cancer and rare diseases. Despite the low rejection rate, our findings suggest that it is critical to improve quality of evidence, focus on risk mitigation strategies as a means of reducing the impact of uncertainties and share HTA practices across borders to increase consistency in decision-making.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"264-283"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Time for a paradigm shift? Exploring competition regulation and its relationship with the rising global burden of industrial epidemics. 是时候转变思维模式了？探讨竞争管制及其与工业流行病日益加重的全球负担的关系。

IF 3 3区医学

Health Economics Policy and Law Pub Date : 2025-06-11 DOI: 10.1017/S1744133125000131

Benjamin Wood, Sven Gallasch, Nicholas Shaxson, Katherine Sievert, Gary Sacks

{"title":"Time for a paradigm shift? Exploring competition regulation and its relationship with the rising global burden of industrial epidemics.","authors":"Benjamin Wood, Sven Gallasch, Nicholas Shaxson, Katherine Sievert, Gary Sacks","doi":"10.1017/S1744133125000131","DOIUrl":"https://doi.org/10.1017/S1744133125000131","url":null,"abstract":"Competition regulation plays a key role in determining firm size, market structure, and what firms can do with their market power. In this paper, we explore how competition regulation in many countries has largely tolerated rising industry concentration and market power in harmful consumer product industries, which, in turn, has likely facilitated an increase in preventable death and disease associated with such industries (ie. industrial epidemics). One important reason for this tolerance has been the rise of the 'consumer welfare' standard, which contends that competition regulators should only focus on a narrow set of concerns mostly relating to consumer price and output. Yet, recent developments shed light on potential avenues through which competition regulation could work more synergistically with public health policies and programmes. While discussions on how to leverage competition regulation along these lines are invariably contested and complex, we argue that it is critical that public health advocates engage with these discussions.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"1-17"},"PeriodicalIF":3.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary care as determinant of COVID-19 and influenza vaccine uptake. 初级保健是COVID-19和流感疫苗接种的决定因素。

IF 3 3区医学

Health Economics Policy and Law Pub Date : 2025-06-11 DOI: 10.1017/S1744133125100108

Zuzana Kotherová, Christophe Premat

{"title":"Primary care as determinant of COVID-19 and influenza vaccine uptake.","authors":"Zuzana Kotherová, Christophe Premat","doi":"10.1017/S1744133125100108","DOIUrl":"https://doi.org/10.1017/S1744133125100108","url":null,"abstract":"This article examines the relationship between primary care (PC) settings and the uptake of COVID-19 and influenza vaccines in 29 European countries. Using multiple linear regression, the study evaluates whether PC settings influence vaccine uptake (VU) for these two vaccines. Based on secondary data, the study shows that people behave differently in the context of COVID-19 and influenza vaccination. Our findings suggest that health systems relied less on PC during the pandemic, not fully using its potential for COVID-19 vaccination. Even if the bivariate correlations highlight the importance of PC, the regression analysis did not verify a direct relation between PC strength and the COVID-19 VU. In contrast, for influenza vaccination, PC strength was the only significant variable. The core research message is that systematic comparative evidence regarding the relation between PC and VU is needed. Based on the belief that appropriate PC setting and adequate general practitioners (GP) involvement in vaccination could contribute to higher VU, the main policy implication of the research is that more attention needs to be paid to PC setting and the role of GPs in vaccination policy.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"1-16"},"PeriodicalIF":3.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulated markets and rationalised myths: an institutional perspective on value-based purchasing in the Netherlands. 规范的市场和合理化的神话：荷兰基于价值的购买的制度视角。

IF 3 3区医学

Health Economics Policy and Law Pub Date : 2025-06-05 DOI: 10.1017/S174413312500012X

Gijs Steinmann, Hester van de Bovenkamp, Antoinette de Bont, Lonneke Timmers, Diana Delnoij

{"title":"Regulated markets and rationalised myths: an institutional perspective on value-based purchasing in the Netherlands.","authors":"Gijs Steinmann, Hester van de Bovenkamp, Antoinette de Bont, Lonneke Timmers, Diana Delnoij","doi":"10.1017/S174413312500012X","DOIUrl":"https://doi.org/10.1017/S174413312500012X","url":null,"abstract":"In the Dutch health care system of regulated competition, health insurers are assigned the crucial role of prudent purchasers and expected to critically contract providers based on the quality and prices of their services. Thus far, however, these organisations have struggled to fulfil this role. This study sheds new light on the purchasing behaviour of Dutch health insurers. We examine how insurers perceive the context in which the value-based purchasing of hospital care should take shape, and we draw on insights from institutional theory to frame our analysis. Our findings are based on a series of semi-structured interviews (n = 18) with employees and representatives of several insurer companies whose combined market shares add up to over 90 per cent of all premium payers. Our analysis highlights an environment in which market mechanisms are tangled up with historically rooted budgeting practices, where insurers are pressured to sustain rather than critique hospitals, and where self-regulating medical professionals are firmly supported by society's deep-seated belief in the quality of their services. Like many other organisations, Dutch health insurers tend to conform to their institutional environment. While this conformity may aid them in organisational stability and survival, it also restricts their ability to purchase prudently.","PeriodicalId":46836,"journal":{"name":"Health Economics Policy and Law","volume":" ","pages":"1-16"},"PeriodicalIF":3.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0